Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — ERS Congress 2025
12 slides from Kymera Therapeutics's conference presentation, September 2025
Slide 1: Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults Arsalan Shabbir, MD, PhD, Vice President, Clinical Development Kymera Therapeutics, Inc.
Slide 2: Conflict of Interest Disclosure
Conflict of Interest Disclosure Arsalan Shabbir is an employee with shares and stock options of Kymera Therapeutics, Inc.
Slide 3: Pioneering Targeted Protein Degradation to Invent New Oral Medicines
Pioneering Targeted Protein Degradation to Invent New Oral Medicines Targeted protein degradation (TPD) harnesses the natural cellular homeostasis TPD allows drugging of previously and protein degradation system used to clear out misfolded or accumulated undruggable targets proteins to degrade disea
Slide 4: KT-621: First STAT6-targeted Drug in Clinical Development
KT-621: First STAT6-targeted Drug in Clinical Development S TAT 6 KT-621 FIRST-IN-CLASS TRANSCRIPTION FACTOR ORAL STAT6 DEGRADER • Signal transducer and activator of transcription 6 (STAT6) is an Potential for Dupilumab-like Activity in a Pill essential transcription factor in the interleukin (IL)-4
Slide 5: First-in-Human, Phase 1a Healthy Volunteer Study
KT-621: First-in-Human, Phase 1a Healthy Volunteer Study Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) 118 healthy volunteers were enrolled in Endpoints Parts A and B Part A Part B Primary Single Ascending Dose Multiple Ascending Dose (SAD)
Slide 6: Favorable PK Profile After Single and Multiple Dosing
KT-621: Favorable PK Profile After Single and Multiple Dosing Single Dose PK Profiles Steady-State (Day 14) KT-621 Plasma Concentration (ng/mL) KT-621 Plasma Concentration (ng/mL) 6.25 mg SD n=6 Multi-Dose PK Profiles 1.5 mg QD n=9 25 mg SD n=6 12.5 mg QD n=7 75 mg SD n=6 25 mg QD n=9 200 mg SD n=6
Slide 7: Daily Doses Rapidly Achieve Complete STAT6 Degradation in Blood and Skin
KT-621: Daily Doses Over 14 Days Rapidly Achieve Complete STAT6 Degradation in Blood and Skin 200 STAT6 Degradation in Blood Placebo n=18 100 STAT6 Degradation in Skin Placebo n=17 150 with 14-Day KT-621 Dosing 1.5 mg QD n=9 with 14-Day KT-621 Dosing 1.5 mg QD n=7 100 Change from Baseline Change fro
Slide 8: Daily Doses Achieved Median Eotaxin-3 Reduction of Up to 63%
KT-621: Daily Doses Over 14 Days Achieved Median Eotaxin-3 Reduction of Up to 63% Serum Eotaxin-31 with 14- Eotaxin-3 (CCL26) Day KT-621 Dosing 20 Placebo n=18 Day 14 1.5 mg QD n=9 Eotaxin-3, Arm 12.5 mg QD n=7 (Median % Change 0 from Baseline) Change from Baseline Eotaxin-3, Median % 25 mg QD n=8 5
Slide 9: Daily Doses Achieved Median TARC Reduction of Up to 37%
KT-621: Daily Doses Over 14 Days Achieved Median TARC Reduction of Up to 37% Thymus and Activation-regulated Serum TARC1 with 14-Day KT- 621 Dosing Placebo n=18 Chemokine (TARC) [CCL17] 1.5 mg QD n=9 20 Day 14 12.5 mg QD n=7 TARC (Median % Arm 25 mg QD n=8 Change From Change from Baseline 50 mg QD n
Slide 10: Safety Summary
KT-621: Safety Summary Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo TRAEs by Preferred Term: SAD Cohorts • No Serious Adverse Events SAD SAD • No Severe Adverse Events AE Term (severity) Placebo KT-621 (n=12) (n=36) • No dose dependent pattern in Treatme
Slide 11: First Clinical Proof of Concept for STAT6-targeted Drug
KT-621: First Clinical Proof of Concept for STAT6-targeted Drug • Well-tolerated across all dose levels with safety profile undifferentiated from placebo. • Favorable PK profile after single and multiple daily doses, with rapid absorption after oral dosing and dose-proportional increase in exposure.
Slide 12: Q&A Thank You
Q&A THANK YOU! For more information, view our poster: